19 April 2016, Cambridge, UK – The Precision Medicine Catapult, the UK’s innovation centre for precision medicine, announces today it has appointed Dr Belinda Quinn as its new Chief Executive Officer.
Belinda has been working as Chief Clinical Officer of the Precision Medicine Catapult over the past six months, formulating and landscaping Precision Medicine opportunities across the UK. She has played a pivotal leadership role in mobilising the seven Centres of Excellence integral to the success of the Precision Medicine Catapult.
Belinda trained as a doctor specialising in neurology before diversifying into IT and clinical leadership roles. She has held executive and transformational change roles across the public and private sector including big pharma, global management consulting, the NHS, data and regulatory in the UK, Australia and the Middle East.
Richard Barker, Chairman of the Precision Medicine Catapult said: “Belinda brings deep experience and great energy to the task of building the Precision Medicine Catapult and delivering its strategy. With our ambition to create value for the NHS, private sector companies and most importantly for patients through the development of precision medicine, her ability to bring together all these interests will be invaluable.”
Ruth McKernan, Chief Executive of Innovate UK, the Precision Medicine Catapult primary funder, said: “The Precision Medicine Catapult will transform the UK’s capability for innovation in this important sector, helping to drive economic growth and deliver significant improvements in health. Belinda has already built a strong reputation with colleagues across the UK and I am confident that the Catapult will be a powerful force in making the UK a leader in precision medicine.”
Belinda Quinn said: “I am delighted to accept the role as CEO of the Precision Medicine Catapult and will continue to build on the momentum and progress we have made in the last year. I am excited by the opportunity to work with the many world-leading experts in research and clinical practice that we have in this country, coupled with industry partners and Innovate UK to help bring forward innovative, sustainable and more cost-effective solutions that will build the UK’s precision medicine industry, benefit patients and improve the effectiveness and efficiency of the healthcare system in the UK.”